Liothyronine tablets: suspected excessive and unfair pricing

The CMA is investigating alleged excessive and unfair pricing with respect to liothyronine tablets under Chapter II CA98/Article 102 TFEU.

Case timetable

Date Action
November 2017 Statement of objections issued
November 2017 Decision whether to proceed with the investigation
May 2017 Decision to proceed with the investigation
October 2016 to April 2017 Initial investigation, information gathering, including issuance of formal or information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
October 2016 Investigation opened

Change log

The following changes have been made since the case was opened in October 2016:

Date of change Reason for change Change made to
January 2018 Decision to focus investigation exclusively on liothyronine and de-prioritise investigation into another product Focussing of investigation exclusively on liothyronine
16 October 2017 Additional time for evidence gathering and analysis Date of decision on whether or not to proceed with the investigation extended from September 2017 to November 2017
20 March 2017 Additional time for evidence gathering and analysis Date of decision on whether or not to proceed with the investigation extended from April 2017 to May 2017
20 January 2017 Additional time for evidence gathering and analysis Date of decision on whether or not to proceed with the investigation extended from February to April 2017

Statement of objections

On 21 November 2017 the CMA issued a statement of objections alleging that Concordia has breached UK and EU competition law by charging excessive and unfair prices in relation to the supply of liothyronine tablets in the UK.

Notes

  • The investigation is under Chapter II of the Competition Act 1998 (CA98) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).
  • No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the statement of objections will now have an opportunity to respond to the allegations.
  • The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.
  • Further detail of the CMA’s procedures in Competition Act 1998 cases is available here: CMA’s procedures in Competition Act 1998 cases.
  • Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.

Contacts

Assistant Project Director

Paul Dean (0203 738 6693, paul.dean@cma.gsi.gov.uk)

Project Director

Ronan Flanagan (020 3738 6142, ronan.flanagan@cma.gsi.gov.uk)

Senior Responsible Officer

Geoff Steadman (020 3738 6311, geoff.Steadman@cma.gsi.gov.uk)

Published 25 October 2016
Last updated 21 November 2017 + show all updates
  1. Statement of objections issued.
  2. Timetable updated.
  3. Timetable updated.
  4. Timetable updated.
  5. Timetable updated.
  6. First published.